Latest Gilead Stories
CHICAGO, Sept. 11, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog.
WALTHAM, Mass., June 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of HIV, Gilead and Tibotec (a wholly owned subsidiary of Johnson & Johnson) remain on track to launch three novel treatment options in the next two years - Gilead's Quad (a four drug, one pill, once-daily, regimen), Tibotec's rilpivirine and Gilead/Tibotec's rilpivirine/emtricitabine/tenofovir fixed-dose...
Coach falls from No. 1 to No. 16 NEW YORK, March 26 /PRNewswire/ -- Biopharmaceutical company Gilead Sciences tops the 2009 BusinessWeek 50 ranking of the best performing U.S. companies.